It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ATAI’s FA Score shows that 1 FA rating(s) are green whileTDCX’s FA Score has 0 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ATAI’s TA Score shows that 4 TA indicator(s) are bullish while TDCX’s TA Score has 4 bullish TA indicator(s).
ATAI (@Biotechnology) experienced а +2.68% price change this week, while TDCX (@Miscellaneous Commercial Services) price change was -5.94% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +6.65%. For the same industry, the average monthly price growth was +5.77%, and the average quarterly price growth was +27.21%.
The average weekly price growth across all stocks in the @Miscellaneous Commercial Services industry was +1.02%. For the same industry, the average monthly price growth was +3.58%, and the average quarterly price growth was +8.52%.
ATAI is expected to report earnings on Mar 27, 2024.
Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.@Miscellaneous Commercial Services (+1.02% weekly)
The sector produces general business services, and are not classified elsewhere. For example, FleetCor Technologies provides fuel cards and workforce payment products and services; Copart, Inc. provides online vehicle auction and remarketing services across various nations; Equifax Inc. collects and aggregates credit information on consumers and businesses worldwide, along with selling credit monitoring and fraud-prevention services. Many of the companies in this category have multi-billion market capitalizations.
|ATAI||TDCX||ATAI / TDCX|
overvalued / fair valued / undervalued
PROFIT vs RISK RATING
PRICE GROWTH RATING
P/E GROWTH RATING
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
3 days ago90%
1 day ago67%
1 day ago89%
1 day ago83%
1 day ago86%
1 day ago80%
1 day ago79%
1 day ago76%
1 day ago84%
1 day ago84%
1 day ago87%
4 days ago74%
7 days ago80%
8 days ago86%
1 day ago87%
1 day ago90%
1 day ago89%
1 day ago71%
|MFs / NAME||Price $||Chg $||Chg %|
|Putnam Dynamic Asset Allocation Bal A|
|Invesco Diversified Dividend A|
|Morgan Stanley Developing Opportunity C|
|Delaware Ivy Natural Resources I|
|Hennessy Cornerstone Mid Cap 30 Inv|
A.I.dvisor tells us that TDCX and ARLO have been poorly correlated (+31% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that TDCX and ARLO's prices will move in lockstep.